Quick Facts: Therapeutic Domains

• Primary Use: Provides support for smoking cessation in adults.
• Patient Goal: Aids in reducing the use of tobacco products.
• Benefit: May help individuals manage the symptoms associated with nicotine dependence.

---

Tabex, which contains the active substance cytisine, is used as a therapeutic intervention to help adult individuals quit smoking. The primary role of this medication is to support an individual's efforts in achieving abstinence from tobacco products. It may assist in reducing the desire to smoke and help manage the discomfort or urge associated with decreasing nicotine intake.

Available and utilized in several countries, particularly in Central and Eastern Europe, the medication provides a pharmacological tool to support behavioral changes for those seeking to overcome nicotine dependence. Cytisine is used as a treatment option within established clinical frameworks for tobacco cessation in adults. Data suggests that cytisine may increase the likelihood of achieving successful smoking cessation compared to not using a pharmacological aid. Using this medication is generally considered part of a broader plan that incorporates a firm commitment to stopping smoking and may involve counseling or behavioral support, as recommended by healthcare professionals.

Regulatory References

1. WHO EML application for cytisine inclusion

The eligibility for Tabex (Cytisine) is strictly defined by regulatory documents, which identify specific populations and conditions that prohibit or restrict its use.

Eligibility Scope

Category	Official Regulatory Status
Populations for whom use is allowed	Adults (18 years and older) who are smokers with a serious intention to quit.
Populations for whom use is contraindicated	Patients with known hypersensitivity to Cytisine; pregnancy or breastfeeding; unstable angina; history of recent myocardial infarction or stroke; and clinically significant arrhythmias.

Condition-Specific Eligibility Rules

Classification	Restricted Groups (Not Recommended)
Age-Related	Persons under 18 and patients over 65 (due to limited or unestablished safety data).
Organ Function	Patients with renal impairment or hepatic impairment (due to a lack of clinical experience in these groups).

Use is also permitted only with caution in individuals with pre-existing conditions such as hypertension, heart failure, diabetes, gastric or duodenal ulcer, or a history of schizophrenia.

The official regulatory profile for Tabex (Cytisine) defines several interaction constraints primarily related to mandated prohibitions and the physiological effects of successful smoking cessation.

Interaction Restrictions and Classifications

The medicine is restricted for co-administration with anti-tuberculosis drugs due to the officially documented risk of increased side effects. A separate pharmacodynamic interaction exists with nicotine-containing products, including continued smoking, which could lead to aggravated adverse reactions of nicotine. This co-use is restricted by regulatory documents.

Pharmacokinetic Changes

The most significant pharmacokinetic interaction is indirect, resulting from smoking cessation itself. Tobacco smoke induces the metabolism of drugs processed by the CYP1A2 enzyme. When an individual stops smoking, this induction reverses, potentially causing a rise in the plasma concentration of co-administered CYP1A2 substrates. Examples listed in official documents include Theophylline, Clozapine, and Ropinirole.

Required Contraceptive Measure

A specific interaction-related restriction applies to systemically acting hormonal contraceptives. As the drug’s impact on contraceptive effectiveness is not known, regulatory documents state that women using these products must use a second barrier method during the course of treatment. The drug can be taken with or without food.

The mechanism of action for the active substance, Cytisine, is defined by its precise interaction with neuronal receptors in the central nervous system, resulting in a unique dual biological effect that operates via specific neuronal receptors.

---

Dual Action: Partial Agonism and Competitive Blockade

This domain covers Cytisine's interaction with its main biological target, the neuronal alpha4beta2 nicotinic acetylcholine receptors ( nAChRs). By acting as a partial agonist, the drug triggers a controlled, moderate release of dopamine in the brain's reward pathway, leading to the maintenance of moderate, sub-maximal dopamine release. Simultaneously, Cytisine acts as a competitive antagonist, physically occupying the same nAChR sites, which prevents exogenous nicotine from binding and causing the full, powerful activation that produces a high-level activation of the mesolimbic pathway.

---

Modulation of Central Reward Pathways

The resulting neurochemical cascade primarily affects the Mesolimbic Dopamine Pathway in the central nervous system. The drug's mechanism sustains baseline neurotransmitter activity while effectively abolishing the full-scale activation of the central reward pathway by exogenous nicotine. This systemic modulation constitutes the central component of the drug's physiological effect, although secondary effects, such as mild stimulation of autonomic reflexes and respiration, are also involved via peripheral receptor activity. The entire mechanism relies on maintaining sufficient alpha4beta2 receptor occupancy, which is a key mechanistic constraint related to the duration of the biological effect.

How to Use Tabex: Administration Guidelines

Tabex, which contains the active substance cytisine, is administered via the oral route as a 1.5 mg film-coated tablet. The treatment regimen is structured as a 25-day course involving a gradually decreasing dose intended to support complete cessation of tobacco use.

The standard protocol requires individuals to establish a target quit date for smoking, which must be no later than the fifth day of the treatment course. The tablets should be swallowed whole with a suitable amount of water and may be taken with or without food.

---

Dosing and Schedule Principles

The regimen begins with a higher frequency of administration, which is tapered down over the 25-day period:

Treatment Days	Dose Frequency	Maximum Daily Dose
Days 1 to 3	One tablet every 2 hours	6 tablets (9 mg)
Days 4 to 12	One tablet every 2.5 hours	5 tablets (7.5 mg)
Days 13 to 16	One tablet every 3 hours	4 tablets (6 mg)
Days 17 to 20	One tablet every 5 hours	3 tablets (4.5 mg)
Days 21 to 25	One to two tablets daily	2 tablets (3 mg)

---

Administration Rules and Procedural Constraints

The 25-day cycle constitutes a complete course of therapy. If a dose is missed, it is recommended to skip the forgotten dose and resume the schedule at the next designated time without taking a double dose. If the treatment fails and the individual resumes smoking, the course may be resumed after 2 to 3 months. The treatment is not recommended for use in individuals under 18 years of age or over 65 years, or in those with pre-existing renal or hepatic impairment, due to limited clinical experience in these populations.

Research Evidence / Overview of Studies for Tabex (Cytisine)

---

Evidence for Use in Smoking Cessation in Adults

The evidence supporting the research base for Cytisine, the active ingredient in Tabex, includes randomized controlled trials (RCTs). These studies were studied for its use as a pharmacological aid for adults seeking to stop using tobacco products. Research examined continuous smoking abstinence and other related outcomes, often with confirmation using a biomarker test, such as measuring carbon monoxide levels in the breath.

Findings describe patterns observed in the studies in the adult populations who were motivated to quit smoking. Research highlights changes measured during the study period, reporting the rates of abstinence observed in the group receiving Cytisine compared to a group receiving a placebo (an inactive treatment). The overall evidence certainty from scientific bodies is generally categorized as moderate when comparing the results against a placebo. Studies contribute to the broader evidence landscape by examining how patient-reported outcomes describing perceived discomfort, particularly the physical craving associated with nicotine withdrawal, evolved in the observed populations.

---

Comparing Cytisine to Other Pharmacological Aids

Research has also explored how Cytisine was evaluated in studies against other commonly available pharmacological aids used for quitting smoking. These comparative studies were designed to monitor whether different pharmacological approaches were associated with varied rates of achieving abstinence.

Data show patterns related to how abstinence rates in the Cytisine group compared to those using other smoking cessation treatments. While some studies indicate comparable results, the evidence for these direct head-to-head comparisons is generally considered to have a low-to-moderate certainty. This is primarily because the volume of research specifically focused on these direct comparisons remains modest, and the data for certain groups remain insufficient to draw clear conclusions about specific direct comparisons against other pharmacological treatments.

---

Key Research Limitations and Uncertainties

Researchers and regulators point to several key research limitation frames that need further study. One main area of uncertainty relates to the heterogeneity (variability) across studies, particularly concerning the type and duration of the dosing schedule used—for example, the traditional 25-day regimen versus newer, longer courses.

Additionally, while studies monitored responses over defined time intervals up to a year, long-term status of non-smoking is not fully established beyond that point. Research exploring short-term symptom changes was observed in more studies, but data for certain groups remain insufficient, and more focused studies are necessary to provide greater certainty.

Key Studies & References Application to add cytisine to the WHO Model List of Essential Medicines

Common questions about Tabex (FAQ)

Q: Is Tabex suitable for people who have mild heart conditions?

Official documents state that Tabex is strictly contraindicated for individuals with severe heart problems, such as a recent heart attack, unstable angina, or clinically significant arrhythmias. Caution is advised for those with other pre-existing conditions like heart failure or uncontrolled hypertension. For individuals with any type of heart condition, careful consideration of their eligibility is necessary, particularly when conditions requiring caution are present.

Q: How is Tabex different from varenicline or bupropion?

The active ingredient in Tabex, cytisine, is chemically different from varenicline, though both work as a partial agonist on nicotine receptors in the brain. Bupropion works through a distinct mechanism entirely, as it is classified as an atypical antidepressant. These facts are consistent with regulatory and clinical reviews.

Q: What does current research say about the long-term use of Tabex?

Official reviews confirm that the drug’s safety profile is supported during the standard 25-day treatment course. While research has examined follow-up for smoking abstinence rates over periods up to 12 months, the long-term safety of the medicine when used beyond the recommended treatment duration is not consistently defined in regulatory reviews.

Q: Can Tabex treatment be repeated if necessary?

According to the official product information, if an individual resumes smoking after an unsuccessful treatment, the entire course may only be repeated after a waiting period of two to three months. This restriction on repeating the treatment is specified in regulatory documents.

Q: Is Tabex available as an over-the-counter medicine in certain regions?

The regulatory status of Tabex can differ depending on the specific country where it is marketed. Official information indicates that in most regions where it has received marketing authorization, it is supplied as a prescription-only medicine.

Q: Are there different strengths or formulations of Tabex available?

The standard formulation detailed in regulatory documents is a 1.5 mg film-coated tablet, which is administered according to a specific tapering schedule. Official product information does not consistently list other licensed strengths or different forms of the medicine.

Q: Does Tabex work by blocking nicotine receptors?

The mechanism of action is described as a dual function. The active ingredient, cytisine, acts as a competitive antagonist, meaning it physically competes with and displaces nicotine, partially blocking its full effect. At the same time, it acts as a partial agonist to provide a low-level stimulation to the same receptors.

Q: What are the most serious side effects that have been officially reported?

Official product information classifies adverse reactions based on how frequently they occur, not by their severity. The most serious risks are primarily noted as absolute contraindications (situations where the drug must not be used) involving certain cardiovascular and neurological conditions. Safety warnings also exist about potential changes in thinking or mood, which can be associated with stopping smoking generally.

Q: Is it common for people using Tabex to experience vivid dreams?

According to the official Summary of Product Characteristics, adverse reactions related to sleep disorders are considered Very Common. This classification includes experiencing abnormal dreams or nightmares.

Q: How quickly can someone expect to feel the effects of Tabex?

Pharmacokinetic studies indicate that the active substance reaches its maximum concentration in the bloodstream approximately two hours after an oral dose. This concentration peak is the point at which the drug is most available for its activity in the body.

Q: Why is Tabex available in some countries but not others?

Regulatory and clinical reviews suggest that the medicine’s low cost and established generic structure historically presented limited financial incentive for companies to seek costly regulatory approval in new markets, such as those regulated by the FDA or the EMA.

Q: Is Tabex considered habit-forming or addictive?

Based on the drug’s pharmacological action as a partial agonist that reduces the highly rewarding effect of nicotine, research suggests that the medicine itself is not expected to be addictive or habit-forming.

Q: What are the signs of taking too much Tabex, according to official documents?

Official regulatory documents describe that the symptoms of taking too much of the medicine resemble signs of nicotine intoxication. These may include general malaise, nausea, vomiting, increased heart rate, fluctuations in blood pressure, and breathing problems.

Q: What is the general safety classification of Tabex in the countries where it is approved?

In the countries where it has received marketing authorization, the medicine is generally supplied as a prescription-only medicine. This means that the medicine is administered under the oversight of a healthcare professional.

Q: Are there any official restrictions on driving or operating machinery while taking Tabex?

The official product information advises patients to exercise caution when driving or operating machines during treatment. This advice is provided because the medicine is known to cause side effects such as dizziness and sleep disorders, which could potentially impair attention.

Q: What is the half-life of the active component in Tabex?

According to human pharmacokinetic studies, the active component, cytisine, has a relatively short half-life, which is reported to be approximately 4.8 hours.

Storage and Disposal Requirements for Tabex

Official regulatory documents define strict conditions for the storage and disposal of Tabex (cytisine) tablets. The medicine must be stored below 25 C to maintain its stability.

Storage Constraint	Requirement
Temperature	Store below 25 C
Protection	Keep in the original container to protect from light and moisture
Safety	Keep out of the sight and reach of children
Stability	Do not use after the stated expiry date

For disposal, unused or expired Tabex must not be thrown away with household waste or wastewater. These disposal measures are intended to help protect the environment. Patients are instructed to consult a pharmacist for guidance on the proper method for discarding medicines no longer required.